First page of the Report "GMP Issues With COVID Vaccines and Drugs are Not New Concerns"

Report – GMP Issues With COVID Vaccines and Drugs are Not New Concerns

By

Barbara W. Unger

,

Areas examined in this report:

Why three manufacturing sites for COVID-19 vaccines and drugs received 483 observations
An in-depth analysis of these observations based on the author’s expertise
Learn how these observations stack up with observations at non-COVID products

If you have trouble with the form, please contact events@redica.com.

Access the white paper

If you have trouble with the form, please contact events@redica.com.